Plecanatide is an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, it is approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

ODQ is a selective and irreversible inhibitor of nitric oxide-sensitive guanylyl cyclase.

Vericiguat targets soluble guanylate cyclase (sGC) and is used for treating heart failure.

BAY 41-2272 is an activator of guanylate cyclases (sGC).

Ataciguat is a potent guanylate cyclase activator potentially for the treatment of aortic valve stenosis.

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM - 1.1 μM.

Cinaciguat is the first of a class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.

Riociguat acts as stimulator of soluble guanylate cyclase (sGC) that is used to treat ipulmonary hypertension.

BAY 41-8543 reverses PAH and vascular structural remodeling in MCT-treated rats as a pulmonary hypertension treatment molecule.